Skip to main content

Privigen FDA Approval History

FDA Approved: Yes (First approved July 26, 2007)
Brand name: Privigen
Generic name: immune globulin intravenous (human)
Dosage form: Liquid
Company: CSL Behring
Treatment for: Primary Immunodeficiency Syndrome, Immune Thrombocytopenia, Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of primary humoral immunodeficiency (PI), chronic immune thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).

Development timeline for Privigen

DateArticle
Sep 14, 2017Approval CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
Apr 19, 2010Approval CSL Behring Receives FDA Approval to Extend Shelf Life for Privigen from 24 to 36 Months
Jul 27, 2007Approval CSL Behring Announces FDA Approval of Privigen-- First Proline-Stabilized 10 Percent Liquid IVIg

See also

Privigen (immune globulin intravenous (human)) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer